Results 141 to 150 of about 59,353 (325)

Surgical debulking is associated with improved survival in stage I–II diffuse large cell lymphoma [PDF]

, 1990
Jorge Romaguera, William S. Velasquez, K B Silvermintz, Lillian B. Fuller, Fredrick B. Hagemeister, Peter McLaughlin, Fernando Cabanillas   +6 more
openalex   +1 more source

PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis

Journal of Neuroendocrinology, EarlyView.
Abstract Patients with bulky neuroendocrine liver metastases (NELM) undergoing PRRT with [177Lu]Lu‐DOTATATE have a worse survival than patients with limited liver metastases. Previously, the safety and efficacy of additional selective internal radiotherapy (SIRT), using holmium‐166 (166Ho)‐microspheres, directly following PRRT in patients with NELM ...
W. B. Veldhuis, T. Walter, D. M. V. de Vries‐Huizing, J. Theysohn, S. Barton, E. D. Ekkelenkamp, B. Lachachi, R. J. G. de Jong, L. W. van Golen, H. Lanzafame, L. Milot, H. Lahner, M. E. G. H. Lam, M. E. T. Tesselaar, A. J. A. T. Braat   +14 more
wiley   +1 more source

Role of primary surgery in advanced ovarian cancer

World Journal of Surgical Oncology, 2004
Background Major issues in surgery for advanced ovarian cancer remain unresolved. Existing treatment guidelines are supported by a few published reports and fewer prospective randomized clinical trials.
Franke Folker E, Münstedt Karsten
doaj   +1 more source

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy [PDF]

, 2017
BACKGROUND: Current standard neoadjuvant treatment for advanced ovarian cancer is 3-weekly platinum-based chemotherapy (CP3w). Patients unable to have interval debulking surgery (IDS) or with significant residual disease have a poor outcome to CP3w ...
Hackshaw, A, Kristeleit, R, Ledermann, JA, Luvero, D, MacDonald, N, McCormack, M, Milani, A, Mould, T, Olatain, A, Raja, F, Widschwendter, M   +10 more
core   +1 more source

The peritoneal tumour microenvironment of high-grade serous ovarian cancer [PDF]

, 2012
High-grade serous ovarian cancer (HGSC) disseminates early and extensively throughout the peritoneal space, causing multiple lesions that are a major clinical problem. The aim of this study was to investigate the cellular composition of peritoneal tumour
Balkwill, F.R., Cooper, D., Ennis, D.P., Everitt, G., Gavins, F.N.E., Gould, D., Kulbe, H., Leinster, D.A., Lockley, M., Mcneish, I.A., Nourshargh, S., Perretti, M., Thompson, R.   +12 more
core   +3 more sources

Clinical manifestations of Florida spot keratopathy in dogs and cats: One hundred cases (2021–2024)

Veterinary Ophthalmology, EarlyView.
Abstract Purpose This study describes the ocular findings in dogs and cats diagnosed with Florida spot keratopathy (FSK) at a single institution. Methods Affected animals underwent a single comprehensive ophthalmic examination, with no follow‐ups conducted. Data on patient demographics and clinical findings were collected and analyzed. Results Based on
O. Pe'er, K. W. Handel, D. Arad, L. Sebbag, R. Ofri   +4 more
wiley   +1 more source

Bronchoscopic debulking of a feline tracheobronchial carcinoma and long-term outcome

Journal of Feline Medicine and Surgery Open Reports, 2018
Case summary This report describes a 10-year-old female spayed Russian Blue cat presented with a 5 month history of respiratory difficulty. Thoracic radiographs were suggestive of a central airway obstruction.
Marina Dominguez Ruiz, Jessica Grant, Juan Hernandez   +2 more
doaj   +1 more source

Interval Debulking Surgery in Ovarian Cancer

Nepal Journal of Obstetrics and Gynaecology, 1970
Primary debulking surgery’s (PDS) role in ovarian cancer there is no dispute, as the currently accepted management of treatment of advanced stage ovarian cancer is PDS in order to achieve an optimal cytoreduction as the amount of residual tumour is one of the most important prognostic factors for survival of women with epithelial ovarian cancer ...
Meeta Singh, Samjhana Dhakal, Rajshree Jha   +2 more
openaire   +3 more sources

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease.
Pawel Kordowitzki, Britta Lange, Kevin M. Elias, Marcia C. Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli   +6 more
wiley   +1 more source

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Trials
Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy ...
Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng   +9 more
doaj   +1 more source